ANVS Annovis Bio, Inc.
Listings ·
The NYSE accepted Annovis Bio's plan to regain compliance with its market capitalization and stockholders' equity standards, giving the company 18 months from a March 26, 2025 notice, quarterly progress reports and a warning that trading could still be suspended.
The NYSE says Annovis's 30-day average market capitalization was approximately $37.9 million and its stockholders' equity was $9.3 million, both under the $50 million floor. The company's 10-K already carries a going-concern warning and says its cash lasts into the fourth quarter of 2025.
Annovis Bio priced 5,250,000 units at $4.00 for $21,000,000 on February 3, 2025, through ThinkEquity as underwriter, with a $1,260,000 discount and warrants exercisable at $5.00, which is 125% of the offering price.
| Line | FY2025 | FY2024 |
|---|---|---|
| Revenue | $0 | $0 |
| Research and development | $25.2 million | $20.0 million |
| Net income (loss) | -$28.9 million | -$24.6 million |
| Cash from operations | -$25.6 million | -$21.9 million |
| Cash and equivalents | $19.5 million | $10.6 million |
Our latest story on this, dated Mar 27, 2025: "Annovis Bio gets NYSE continued listing notice, will submit compliance plan within 45 days". The story links the filing or release it is based on. Read the story.
Our latest story on this, dated Feb 3, 2025: "Annovis Bio prices $21,000,000 public offering of units at $4.00". The story links the filing or release it is based on. Read the story.
Annovis Bio, Inc. trades under the ticker ANVS on NYSE.
Annovis Bio, Inc. is listed on NYSE. Our directory also records these other listings: GETTEX:07X.
The SEC Central Index Key (CIK) for Annovis Bio, Inc. is 1477845. Its filings are on SEC EDGAR.
42,606,152 shares as of 2026-08-14, per the cover page of its 10-Q filed 2026-08-14.
Our directory records Annovis Bio, Inc. under United States.
Our directory classifies Annovis Bio, Inc. as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline.
The ISIN recorded for Annovis Bio, Inc. is US03615A1088.
aibio.space lists Annovis Bio, Inc. among 2,820 public biotech companies and publishes its news here as stories appear.
SEC records list its state or country of incorporation as DE.
$0 for the fiscal year ended Dec 31, 2025, as reported to the SEC.
Annovis Bio, Inc. reported a net loss of $28.9 million for the fiscal year ended Dec 31, 2025, and used $25.6 million of cash in operations, per its annual report to the SEC.
$25.2 million in the fiscal year ended Dec 31, 2025, per its annual report.
$18.7 million in cash at Jun 30, 2026, per its 10-Q.
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01,7.01,9.01). Source
Reported a financing. SEC Form 424B5. Source
Reported substantial doubt about its ability to continue as a going concern. SEC Form 10-K. Source
Disclosed a shareholder lawsuit, subpoena or other legal matter. SEC Form 10-K. Source
Reported a financing. SEC Form 424B5. Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 7.01,9.01). Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01,5.02,7.01,9.01). Source
Reported substantial doubt about its ability to continue as a going concern. SEC Form 10-K. Source
Disclosed a shareholder lawsuit, subpoena or other legal matter. SEC Form 10-K. Source
Reported a financing. SEC Form 424B5. Source
Reported a financing. SEC Form 424B5. Source
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio